AUTHORS
Rupsa C Boelig, MD, Mrutyunjaya Bellad, MD2, Manjunath Somannavar3, Michael Georgieff, MD4, Ben Leiby, PhD5, Rebecca Hartman6, Richard Derman, MD7
AFFILIATIONS
1 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
2 KLE Academy of Higher Education and Research’s J N Medical College, Belagavi, India
3 KLE Academy of Higher Education and Research’s J N Medical College, Belagavi, India
4 University of Minnesota, Minneapolis, Minnesota, United States, University of Minnesota, Minneapolis, Minnesota, United States
5 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
6 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
7 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
ABSTRACT
Background: In a recent multicenter randomized controlled trial in India comparing intravenous to oral iron for early intervention of maternal anemia, ~30% of participants in all arms failed to achieve Hb ≥11.0g/dL by delivery. We aim to describe the relationship between ferritin through gestation and the likelihood of achieving anemia resolution (Hb ≥11.0g/dL) by delivery
Methods: This is a secondary analysis of a multi-center randomized controlled trial in India comparing single dose intravenous (IV) iron (ferric carboxymaltose or derisomaltose) to oral iron for moderate IDA (Hb 7.0-9.9g/dL) at 14-17 weeks gestation. All participants had confirmed iron deficiency by either ferritin<30 or transferrin saturation<20% at baseline. We included those randomized to IV iron and who received treatment they were randomized to and excluded those with preterm birth, missing values at 20-24 weeks or delivery, or any additional (non-study) iron therapy/blood transfusion prior to delivery. Ferritin was assessed at baseline (12-16 weeks gestation, pre-treatment), at 20-24 weeks (~4 weeks post treatment), and at 26-30 weeks gestation. The primary outcome for this analysis was anemia resolution at delivery (maternal Hb≥11.0g/dL). We generated latent class models for ferritin change across study visits and evaluated the difference in rates of anemia resolution by delivery in each class. The two IV iron arms were combined for this secondary analysis. Ferritin reported as geometric mean (ng/ml), 95% confidence interval.
Findings: 2,134 of 4,368 in trial were included: 1091, and 1043 received IV ferric derisomaltose, and IV ferric carboxy maltose respectively, and overall rate of anemia resolution at delivery was 62% (1333/2134). In general, those treated with IV iron demonstrated a rise in ferritin at 20-24 weeks, and subsequent decline at 26-30 weeks. Six distinct ferritin class patterns through gestation were noted with significant differences in rates of anemia resolution by class pattern (p<0.001). The two patterns with the highest rate of anemia resolution demonstrated degrees of robust ferritin response at 20-24 weeks (geometric mean 138±(133, 141) and 62 (60,65) respectively) but subsequent decline at 26-30 weeks, with rates of anemia resolution of 67% and 61% respectively. These two were the most common patterns, including 85% of the study cohort (1,826/2,134). The third class pattern demonstrated low ferritin (geometric mean 11 (10,12)) initially with limited improvement across study visits, and with only 53% demonstrating anemia resolution by delivery. The 4th and 5th class patterns were unique in that they both had sharp rise in ferritin at 26-30 weeks (mean 78 (69,89) and 188 (163, 218) respectively), likely reflecting a new inflammatory state in the 3rd trimester, and both had <50% anemia resolution by delivery. The final class pattern demonstrated high ferritin at baseline (mean 117 (98, 139) at baseline, and similarly had <50% anemia resolution by delivery.
Conclusions: For pregnancies complicated by moderate iron deficiency anemia treated with IV iron at 14-17 weeks, distinct patters of ferritin through gestation are associated with anemia resolution by delivery vs not. An initial robust ferritin response at 20-24 weeks after therapy at 14-17 weeks gestation is associated with the greatest rate of anemia resolution by delivery; but given the observed decline at 26-30 weeks there is a significant proportion who would benefit from an additional course of IV iron in the 3rd trimester to achieve anemia resolution by delivery. In contrast, a paradoxical high ferritin, either at baseline, or in 3rd trimester, is associated with <50% rates of anemia resolution by delivery, and likely reflect the adverse impact of inflammatory states on iron mobilization. Our findings help elucidate the physiology of ferritin response through gestation after a single dose IV iron infusion, and highlight how a significant proportion of pregnancies with moderate IDA benefit from additional monitoring and therapy (either additional IV iron or treatment of inflammatory conditions) in order to achieve anemia resolution by delivery.
DISCLOSURES
Rupsa C Boelig, MD: COVIS Pharma - Research Funding